Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
The 18-year-old, Chirag Chikkara clinched a gold medal in the men’s freestyle 57kg categ
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
- Ecuador ready to make history against Uruguay: Beccacece
- Divanshi wins second gold as India sweep women's 25m standard pistol at Lima Junior Worlds
AstraZeneca does not raise high blood clot risk post 2nd dose: Study Last Updated : 29 Jul 2021 05:10:40 PM IST The incidence of rare blood clot is higher following a Covid-19 infection than two doses of AstraZeneca or Pfizer/BioNTech vaccines, according to a new study.
The rates of venous thromboembolism (VTE) -- a combination of deep vein thrombosis and pulmonary embolism -- after first-dose of the AstraZeneca or Pfizer/BioNTech vaccines is 1.3 fold. However, the risk increases 8-fold after diagnosis of Covid-19, revealed the study led and funded by the British-Swedish drugmaker. It is published as a pre-print on The Lancet server.The study assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an Pfizer/BioNTech mRNA vaccine or AstraZeneca's Vaxzevria jab, known as Covishield in India, in over one million individuals.Thromboembolism is the obstruction of a blood vessel by a blood clot that has become dislodged from another site in the circulation, while thrombocytopenia is a low number of platelets in the blood.The results were then compared with expected rates in a general population and in people with Covid-19.The findings showed that "safety profiles of AstraZeneca, and the mRNA-based vaccine were similar and overall favourable".Very rare clotting disorders (TTS) were observed with both vaccines but these were in line with what would be expected in the general population and lower than in those diagnosed with Covid-19, the study showed."This real-world study offers further evidence of the favourable benefit:risk profile of Vaxzeria and demonstrates the critical role all Covid-19 vaccines are playing in combating the pandemic," said Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, in a statement.The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 AstraZeneca participants, conducted between December 27, 2020 and May 19, 2021. It also included 222,710 Covid-19 participants identified between September 1, 2020 and March 1 2021, and 4,570,149 background participants as of January 1, 2017 from a public health database held in Spain's Catalonia."No specific risk factors or definitive cause for TTS following Covid-19 vaccination have been identified and AstraZeneca continues to perform and support ongoing investigations of potential mechanisms," the study noted.Further, these very rare events can be managed when symptoms are identified and treated appropriately, it added.AstraZeneca Covid jab uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.The vaccine has been granted a conditional marketing authorisation or emergency use in more than 80 countries across six continents, the company said.More than 800 million doses of Covid-19 Vaccine AstraZeneca have been supplied to more than 170 countries worldwide, including more than 100 countries through the Covax Facility.IANS London For Latest Updates Please-
Join us on
Follow us on
172.31.16.186